DiaMedica Therapeutics Inc <DMAC.OQ> expected to post a loss of 19 cents a share - Earnings Preview
DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for DiaMedica Therapeutics Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $12.00, about 64.8% above its last closing price of $4.22
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.17 | -0.18 | -0.18 | Met | 0 |
Dec. 31 2025 | -0.17 | -0.18 | Missed | -4.3 | |
Sep. 30 2024 | -0.15 | -0.15 | -0.15 | Met | 3.2 |
Jun. 30 2024 | -0.15 | -0.16 | -0.13 | Beat | 17 |
Mar. 31 2024 | -0.16 | -0.16 | -0.14 | Beat | 10.6 |
Dec. 31 2023 | -0.14 | -0.14 | Met | 0 | |
Sep. 30 2023 | -0.14 | -0.13 | -0.12 | Beat | 5.3 |
Jun. 30 2023 | -0.19 | -0.18 | -0.16 | Beat | 9.4 |
This summary was machine generated August 1 at 11:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
